In high risk prostate cancer treated with RT with neoadjuvant/concurrent ADT, is adjuvant intermittent ADT reasonable instead of continuous ADT?  

As an option in general, I say no. Given multiple phase III trials showing an overall survival benefit of adjuvant ADT, I would need a robust non-inferiority study of intermittent ADT to recommend it. If a patient refuses or cannot tolerate continuous ADT but can tolerate intermittent, this is prob...